AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 31486684
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with Deferoxamine (DFO) and Deferasirox (DFX)
Trial: 22713632
Drug: Alfentanil (μ‐opioid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfentanil (μ‐opioid receptor agonist)
Trial: 15890794
Drug: Graded doses
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Graded doses of a selective gonadotropin releasing hormone (GnRH)‐receptor antagonist
Trial: 12523577
Drug: Antithymocyte globulin
RxNorm normalized name: Rabbit antithymocyte globulin
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antithymocyte globulin (ATG) 7.5 to 15 mg/kg
Trial: 9713561
Drug: Induced hypocalcaemia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induced hypocalcaemia (blood ionized calcium lowered by 0.20 mmol/l within 30 min)
Trial: 8129213
Drug: Bitolterol mesylate
RxNorm normalized name: Bitolterol Mesylate
DrugBank: Bitolterol (DB00901)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bitolterol mesylate 0.5 to 3.5 mg by continuous-flow nebulization
Trial: 2563320
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Terfenadine and Flurbiprofen
Trial: 28000180
Drug: Testosterone therapy
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone therapy (5-10 g gel/50-100 mg testosterone)
Trial: 28000180
Drug: Placebo (5-10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (5-10 g gel)
Trial: 17602078
Drug: Cisplatin-based chemotherapy
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin-based chemotherapy in patients with p27Kip1-negative tumors
Trial: 17602078
Drug: Cisplatin-based chemotherapy
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin-based chemotherapy in patients with p27Kip1-positive tumors
Trial: 17602078
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no cisplatin-based chemotherapy)
Trial: 9420397
Drug: Therapy for
RxNorm normalized name: nutritional therapy for GSD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapy for malignancies
Trial: 8213706
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg po metoclopramide (single dose)
Trial: 8213706
Drug: Metoclopramide 10
RxNorm normalized name: metoclopramide 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide 10 mg po quid for 7 days
Trial: 29404806
Drug: Ribociclib (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ribociclib (600 mg/day; 3 weeks on/1 week off) plus Letrozole (2.5 mg/day; continuous)
Trial: 28762932
Drug: Multivessel stenting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multivessel stenting using 2nd generation drug covered stents
Trial: 28762932
Drug: Staged revascularization
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Staged revascularization using 2nd generation drug covered stents
Trial: 22027932
Drug: Topical diclofenac
RxNorm normalized name: diclofenac Topical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical diclofenac sodium 0.1% (Voltaren Ophthalmic)
Trial: 22027932
Drug: Topical dexamethasone
RxNorm normalized name: dexamethasone Topical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical dexamethasone sodium phosphate 0.1% (Sterodex)
Trial: 14616980
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E (525 IU daily for 3 months)
Trial: 9582466
Drug: 5‐FU/adrenaline gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5‐FU/adrenaline gel
Trial: 9582466
Drug: 5‐FU/adrenaline solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5‐FU/adrenaline solution
Trial: 9582466
Drug: 5‐FU gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5‐FU gel
Trial: 8345231
Drug: Modified multidrug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified multidrug therapy regimen (rifampicin 600 mg, clofazimine 100 mg, dapsone 100 mg daily for 21 days)
Trial: 8345231
Drug: Standard WHO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard WHO multidrug regimen (rifampicin 600 mg and clofazimine 300 mg monthly, dapsone 100 mg daily, clofazimine 100 mg on alternate days)
Trial: 3578865
Drug: Tetracaine 0.5%/15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetracaine 0.5%/15 mg with 0.2 mg epinephrine
Trial: 3578865
Drug: Bupivacaine 0.5%/20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 0.5%/20 mg without epinephrine
Trial: 31504526
Drug: High Dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High Dose (HD) Influenza Vaccine
Trial: 31504526
Drug: Standard Dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard Dose (SD) Influenza Vaccine
Trial: 22737871
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy group (intratyimpanic dexamethasone and basic drug group treatment)
Trial: 22737871
Drug: Basic drug
RxNorm normalized name: Basic Fuchsin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basic drug group (ganglioside and vinpocetine injection)
Trial: 19437180
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of both programs
Trial: 15790946
Drug: Magnesium sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Magnesium sulfate therapy (64 mmol/L per day, continuous intravenous dose, started within 4 days after SAH and continued until 14 days after occlusion of the aneurysm)
Trial: 11451715
Drug: Reduced-fat spread
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reduced-fat spread enriched with plant sterol esters (1.1 g/d)
Trial: 11451715
Drug: Reduced-fat spread
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reduced-fat spread enriched with plant sterol esters (2.2 g/d)
Trial: 8297739
Drug: CEF (cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEF (cyclophosphamide 600 mg m-2, epidoxorubicin 60 mg m-2 and fluorouracil 600 mg m-2)
Trial: 7975663
Drug: L-arginine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine infusion at a dose of 12.63g in 300 ml of 0.9% NaCl over 90 min
Trial: 378671
Drug: Once daily
RxNorm normalized name: GEL, ONCE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily Sotalol (80 to 320mg/day)
Trial: 378671
Drug: Twice daily
RxNorm normalized name: CAPSULE, TWICE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily Sotalol (80 to 320mg/day)
Trial: 26028098
Drug: 7-day levofloxacin-dexlansoprazole
RxNorm normalized name: Dexlansoprazole
DrugBank: Dexlansoprazole (DB05351)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 7-day levofloxacin-dexlansoprazole based quadruple therapy
Trial: 26028098
Drug: 14-day levofloxacin-dexlansoprazole
RxNorm normalized name: Dexlansoprazole
DrugBank: Dexlansoprazole (DB05351)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 14-day levofloxacin-dexlansoprazole based quadruple therapy
Trial: 21955635
Drug: Subconjunctival bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subconjunctival bevacizumab (1.25 mg/0.1 mL) injected immediately after surgical excision of the pterygium
Trial: 11427642
Drug: Lisinopril (LIS,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril (LIS, n=35)
Trial: 20201749
Drug: Lisinopril (LIS)
RxNorm normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lisinopril (LIS)
Trial: 7750682
Drug: Ranitidine (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine (600 mg/day)
Trial: 7750682
Drug: Lansoprazole (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole (60 mg/day)
Trial: 3386845
Drug: Copolymer 1
RxNorm normalized name: glatiramer (copolymer 1)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Copolymer 1 (COP-1) - daily intramuscular doses of 20 mg (2 patients) and twice daily subcutaneous doses of 15 mg (3 patients)
Trial: 31857264
Drug: NLP in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NLP in combination with ICD-9-CM codes
Trial: 24010917
Drug: 10-valent pneumococcal-Haemophilus
RxNorm normalized name: HAEMOPHILUS INFLUENZAE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-valent pneumococcal-Haemophilus influenzae protein D conjugate vaccine (PHiD-CV)
Trial: 24010917
Drug: Control meningococcal
RxNorm normalized name: MENINGOCOCCAL B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control meningococcal (ACYW135) conjugate vaccine
Trial: 19798013
Drug: Posterior psoas
RxNorm normalized name: posterior pituitary hormones
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Posterior psoas compartment approach (N=18) using 30 mL of 1.5% mepivacaine
Trial: 12923651
Drug: Tomato products
RxNorm normalized name: Tomato
DrugBank: Tomato (DB10573)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tomato products (raw, sauce, and paste) providing approximately eight mg lycopene/day for three weeks (T21)
Trial: 2623032
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg oral d-amphetamine in fasting state (FAST/DRUG)
Trial: 2623032
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg oral d-amphetamine in fed state (FED/DRUG)
Trial: 31056427
Drug: Low-dose CAL02
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose CAL02 (4 mg/kg)
Trial: 31056427
Drug: High-dose CAL02
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose CAL02 (16 mg/kg)
Trial: 21393255
Drug: L-BLP25 liposome
RxNorm normalized name: L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-BLP25 liposome vaccine (1000 μg subcutaneously)
Trial: 21393255
Drug: Cyclophosphamide (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide (300 mg/m2 i.v. single dose)
Trial: 8418246
Drug: Intravenous diaziquone
RxNorm normalized name: Diaziquone
DrugBank: Diaziquone (DB17174)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous diaziquone (AZQ)
Trial: 8418246
Drug: AZQ with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZQ with significant hematologic toxicity requiring dose reduction
Trial: 25069621
Drug: Technology-based intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Technology-based intervention (empirically supported behavior-change strategies, daily skills, self-monitoring text messages with personalized feedback, biweekly counseling calls from a health coach, access to a Facebook support group)
Trial: 20210368
Drug: Rituximab (as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab (as a single agent or in combination with chemotherapy)
Trial: 20210368
Drug: Rituximab added
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab added to CHOP chemotherapy
Trial: 20210368
Drug: Salvage chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salvage chemotherapy followed by autologous haematopoietic cell transplant (autoHCT)
Trial: 12452245
Drug: Epidural morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural morphine 3 mg before skin incision
Trial: 12452245
Drug: Epidural morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural morphine 3 mg after skin incision
Trial: 12452245
Drug: Epidural morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural morphine 3 mg and ketamine 30 mg before skin incision
Trial: 12452245
Drug: Epidural morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural morphine 3 mg and ketamine 30 mg after skin incision
Trial: 10604407
Drug: Beta-carotene 60
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-carotene 60 mg/d for 6 months, followed by randomization to continue beta-carotene or placebo for 12 additional months.
Trial: 10604407
Drug: Placebo after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo after initial beta-carotene treatment.
Trial: 10604407
Drug: Beta-carotene treatment
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-carotene treatment for 6 months.
Trial: 10604407
Drug: Placebo after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo after beta-carotene treatment.
Trial: 7864103
Drug: Growth Hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth Hormone (GH) administration (12.5-24 micrograms.kg-1.day-1; n = 8)
Trial: 20687838
Drug: 3.75 microg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.75 microg AS03A-adjuvanted H1N1 2009 vaccine (1 dose)
Trial: 20687838
Drug: 3.75 microg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.75 microg AS03A-adjuvanted H1N1 2009 vaccine (2 doses)
Trial: 20687838
Drug: 3.75 microg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.75 microg AS03A-adjuvanted H1N1 2009 vaccine (1 or 2 doses)
Trial: 18487212
Drug: Androgen priming
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Androgen priming with anastrozole 1 mg on cycle days 2, 3, and 4, hCG 1250 IU, cetrorelix 3 mg on cycle day 2, rFSH 150 IU from cycle day 5
Trial: 18487212
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group with flexible antagonist protocol
Trial: 10228629
Drug: EMLA pre-treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EMLA pre-treatment
Trial: 10228629
Drug: Vehicle placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle placebo pre-treatment
Trial: 8909454
Drug: Methazolamide (average
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methazolamide (average dose 168 mg/day)
Trial: 1985289
Drug: azathioprine (AZA)
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: azathioprine (AZA) 3.0 mg/kg daily
Trial: 6358645
Drug: Solcoseryl eye
RxNorm normalized name: Solcoseryl
DrugBank: Solcoseryl (DB15794)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solcoseryl eye gel
Trial: 25675560
Drug: Electroacupuncture at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electroacupuncture at Neiguan (PC 6) and Jianshi (PC 5) combined with granisetron injection
Trial: 19890207
Drug: Caffeinated soda
RxNorm normalized name: Magadi soda
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeinated soda (32 oz daily for 1 week)
Trial: 19890207
Drug: Noncaffeinated soda
RxNorm normalized name: Magadi soda
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Noncaffeinated soda (32 oz daily for 1 week)
Trial: 17302650
Drug: Collective exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Collective exercise program (1 hour, twice weekly of walk, strength, balance, and flexibility training)
Trial: 12478880
Drug: Transdermal nicotine
RxNorm normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal nicotine (5 mg/16 hrs)
Trial: 7665718
Drug: Quinine sulfate
RxNorm normalized name: Quinine Sulfate
DrugBank: Quinine (DB00468)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Quinine sulfate (200 to 300 mg every night)
Trial: 31619325
Drug: Twice-daily BG
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily BG testing
Trial: 31619325
Drug: 4-times-daily BG
RxNorm normalized name: bupropion
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4-times-daily BG testing
Trial: 26358287
Drug: Resuspended NPH
RxNorm normalized name: INSULIN,NPH,BEEF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resuspended NPH insulin (R+)
Trial: 26358287
Drug: Nonresuspended NPH
RxNorm normalized name: INSULIN,NPH,BEEF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonresuspended NPH insulin (R- horizontal)
Trial: 26358287
Drug: Nonresuspended NPH
RxNorm normalized name: INSULIN,NPH,BEEF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonresuspended NPH insulin (R- up)
Trial: 26358287
Drug: Nonresuspended NPH
RxNorm normalized name: INSULIN,NPH,BEEF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonresuspended NPH insulin (R- down)
Trial: 22257422
Drug: Inhaled N-acetylcysteine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled N-acetylcysteine (NAC) 352.4 mg by inhalation twice daily
Trial: 22257422
Drug: Inhaled N-acetylcysteine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled N-acetylcysteine (NAC)
Trial: 19463133
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of calcium antagonists and ACE inhibitors
Trial: 15359902
Drug: Timolol gel-forming
RxNorm normalized name: timolol
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Timolol gel-forming solution (Tg)
Trial: 7862918
Drug: Nicotine patch
RxNorm normalized name: Nicotine Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine patch delivering 0 mg per 24 h
Trial: 7862918
Drug: Nicotine patch
RxNorm normalized name: Nicotine Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine patch delivering 22 mg per 24 h
Trial: 7862918
Drug: Nicotine patch
RxNorm normalized name: Nicotine Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine patch delivering 44 mg per 24 h
Trial: 79761
Drug: Control (non-absorbable
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (non-absorbable antibiotics)
Trial: 31742685
Drug: Modular cognitive-behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modular cognitive-behavioral therapy (CBT) consisting of 30 sessions targeting psychotic experiences and depression/anxiety
Trial: 31742685
Drug: Modular cognitive-behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modular cognitive-behavioral therapy (CBT)
Trial: 21426572
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group with oral health education and supervised toothbrushing four times per year
Trial: 17086470
Drug: Multifaceted intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multifaceted intervention (faxed physician reminders with osteoporosis treatment guidelines and patient counseling)
Trial: 8424508
Drug: Epidural fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Epidural fentanyl infusion (10 micrograms/mL)
Trial: 8424508
Drug: Patient-controlled analgesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-controlled analgesia (PCA) with morphine (1.0 mg/mL)
Trial: 3621992
Drug: 0.05% clobetasol
RxNorm normalized name: CLOBETASOL PROPIONATE 0.5 mg in 1 g TOPICAL CREAM [Clobetasol Propionate Cream, 0.05% Clobetasol Propionate Cream, 0.05%]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05% clobetasol propionate ointment applied once daily for 2 weeks
Trial: 3621992
Drug: 1 week
RxNorm normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 week of active treatment followed by 1 week of vehicle alone
Trial: 30587217
Drug: Mindfulness-based group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness-based group psychotherapy ("Mind it!") in addition to existing treatment regime
Trial: 10986782
Drug: Iron-fortified infant
RxNorm normalized name: INFANT FORMULA SMA IRON FORTIFIED CONC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron-fortified infant cereal (10.2 mg iron) and pureed meat (0.75-1.7 mg iron) with whole cow milk for six months
Trial: 30995645
Drug: 0.15% ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.15% ropivacaine + 0.02 μg × kg‐1 × h‐1 DEX (group D1)
Trial: 30995645
Drug: 0.15% ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.15% ropivacaine + 0.05 μg × kg‐1 × h‐1 DEX (group D2)
Trial: 29120262
Drug: Brimonidine Tartrate
RxNorm normalized name: Brimonidine Tartrate
DrugBank: Brimonidine (DB00484)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Brimonidine Tartrate Ophthalmic Solution, 0.025%
Trial: 27090436
Drug: Cholesterol treatment
RxNorm normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholesterol treatment discussion
Trial: 21849206
Drug: Prolonged anticoagulation
RxNorm normalized name: CPDA-1 Anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged anticoagulation therapy suggested for patients with high FVIII and increased TG.
Trial: 16249698
Drug: Probenecid (PBCD)
RxNorm normalized name: Probenecid
DrugBank: Probenecid (DB01032)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Probenecid (PBCD) and protease inhibitors (PIs)